跳至主要内容
临床试验/CTRI/2019/03/018074
CTRI/2019/03/018074已完成未知

Clinical Evaluation of Ashwagandha Standardized Extract (KSM 66) for itsPharmacological Actions on Sleep in Subjects Having Insomnia and HealthySubjects: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Dr D Y Patil Medical College Hospital and Research Center0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Diagnosis of insomnia based on DSM-IV criteria
  • 2. More than 30 minutes to fall asleep and subjective total sleep time of ââ?°Â¤6.5 hours per night (for at least 3 nights per week); and daytime complaints associated with disturbed sleep
  • 3. Habitual bedtime between 8.30 pm to midnight
  • 4. Body Mass Index between 16.5 to 30 kg/sq.m.
  • 5. Subjects able to understand the sleep diary and are able to and willing to fill the sleep log diary and follow other procedures required by the study protocol
  • 6. Subjects who sign the informed written consent

排除标准

  • 1. Pregnant or breast-feeding women or women with positive urinary pregnancy test at screening.
  • 2. Known clinically significant endocrine, metabolic, hepatic, renal, cardiovascular, gastrointestinal, respiratory, haematological or neurological illnesses.
  • 3. Presence of any current psychiatric disorders that are judged by investigator as potentially causing or contributing to insomnia.
  • 4. Subjects who suffer from sleep disorder other than primary insomnia including restless leg syndrome and sleep apnea.
  • 5. Substance dependence/ abuse in the past one year or with alcohol abuse are ineligible.
  • 6. Those using tobacco products during night awakenings.
  • 7. History of seizures or significant head trauma.
  • 8. Subjects who travelled across four or more time zones or worked on night or rotating shifts in previous 7 days before study initiation or who plan to do the same during the study period.
  • 9. Currently taking any medication on a regular basis (except for antihypertensives, antidiabetics, lipid lowering agents and drugs for primary cardiovascular prophylaxis).
  • 10. Any other investigational drug was used within three months prior the entry in this study.
  • 11. Those who cannot be relied upon to comply with the test procedures or are unwilling to give informed consent.

研究者

发起方
Dr D Y Patil Medical College Hospital and Research Center

相似试验